Written and maintained by CASRAI Editorial Board
Last updated
A Pharmacy and Therapeutics (P&T) committee charter is a medical-staff governance document, not a pharmacy operating procedure. It is what turns a hospital’s general regulatory obligation to run a formulary system into an actual standing body with defined members, defined votes, and a defined decision record. Under 42 CFR 482.25(b)(9), the Medicare Condition of Participation for hospital pharmaceutical services, “a formulary system must be established by the medical staff…” — the regulation names the obligation but says nothing about how many members sit on the committee, how it votes, or how conflicts of interest are handled. That detail is written into the charter (and cross-referenced from the medical staff bylaws), and it is exactly the detail a patient-safety officer, quality director, or risk manager needs to read closely: a charter that is silent on quorum, vote delegation, or COI disclosure is a governance gap that shows up first in a survey finding or a formulary decision nobody can defend later.
This page covers what a P&T committee charter actually needs to specify: who sits on it and who votes, how votes are taken, the criteria the committee is supposed to apply to a formulary decision, and the conflict-of-interest policy governing both voting members and the prescribers who bring requests to the committee. It draws on the current ASHP guideline for this exact document, and on the underlying federal Condition of Participation the charter exists to operationalize.
Where the charter sits: regulation, bylaws, and the charter itself
Three documents work together, and it matters which one says what:
- 42 CFR 482.25 (the Condition of Participation) sets the floor: the medical staff is responsible for developing policies and procedures that minimize drug errors, and “this function may be delegated to the hospital’s organized pharmaceutical service” — and separately, under 482.25(b)(9), the medical staff must establish a formulary system. It does not prescribe committee composition, voting rules, or COI handling.
- Medical staff bylaws typically establish the P&T committee as a standing medical-staff committee, define its reporting line (commonly to the medical executive committee), and grant it the authority the charter then operationalizes.
- The charter itself is the operating document: membership categories, voting rules, meeting cadence, standing agenda, and the COI policy that actually governs day-to-day decisions. This is the document most likely to be thin, stale, or silent on exactly the questions that matter when a decision is challenged — and the one worth auditing directly rather than assuming the bylaws already cover it.
Because 482.25(b)(6) also requires that adverse drug reactions and medication errors be reported to the attending physician and, where appropriate, into the hospital’s QAPI program, the charter’s standing agenda is one of the places that reporting loop actually gets closed — see the agenda section below.
Membership and voting structure
The current ASHP guideline on the P&T committee and formulary system (Ciccarello et al., Am J Health-Syst Pharm 2021;78(10):907–918) frames committee composition as deliberately multidisciplinary. Voting membership should draw from “facility medical staff, other prescribers, pharmacists, nurses, and administrators” representing the organization, with additional non-voting or advisory participation from quality-improvement managers, medication-safety leaders, informaticists, and patient and family engagement advisors. None of that is a fixed headcount — ASHP describes categories of representation, not a required number of seats, and a charter should say explicitly which categories carry a vote and which are advisory-only.
Two structural points a charter needs to answer that are easy to leave implicit:
- Voting eligibility by role, not by attendance. The charter should name which seats vote (e.g., physician members from designated specialties, the chief pharmacist or designee, a nursing representative) and which participants — safety officer, informaticist, patient/family advisor — attend and contribute without a vote. Leaving this to informal practice is exactly the kind of gap that surfaces when a close formulary vote is later questioned.
- Multi-facility site representation. For a health system spanning more than one hospital, ASHP is explicit that “site representation needs to be addressed to ensure equitable input and voting authority from each facility” — a single-hospital charter reused unedited across a system’s other facilities is a common way this gets missed.
Quorum, delegation, and how votes are taken
ASHP identifies the administrative components a charter needs to fix, without prescribing the numbers itself: a stated definition of quorum, a stated process to allow or disallow delegation of a vote (a member sending a proxy rather than attending in person), and a stated approach to voting, including whether roll-call votes are used to make the record transparent. ASHP does not set a required quorum percentage or a standard delegation rule — those are institution-specific, the same way ASHP’s own MUE guideline leaves sample size to institutional judgment rather than a fixed number. A charter that omits a quorum definition entirely is not following an ASHP default; it is simply missing the provision.
What a complete voting section should specify, at minimum: quorum (a count or a proportion of voting seats), whether members can delegate their vote and to whom, whether votes are recorded by roll call or by simple show-of-hands/consensus, and how a tie is resolved (commonly the chair’s vote, but the charter should say so rather than leave it to the moment).
Formulary-decision criteria
ASHP’s guideline states that formulary decisions should be “founded on the evidence-based clinical, ethical, legal, social, logistical, philosophical, quality-of-life, safety, and economic factors” relevant to a drug’s use — a broader test than “does it work and what does it cost.” In practice, the charter (or the formulary policy it references) should require:
- A systematic review of the biomedical literature for the specific request, not a vendor summary.
- A pharmacoeconomic assessment where relevant — cost is a legitimate factor, but the criteria list makes clear it is one factor among several, not the sole gate.
- Internal utilization data and benchmarking against comparable organizations.
- Explicit consideration of patient-safety factors: adverse-effect profile, REMS requirements, and how the addition interacts with existing look-alike/sound-alike or high-alert medication safeguards already on the formulary.
A formulary decision the committee makes often generates downstream work that belongs on the standing agenda rather than being handled ad hoc — most directly, a medication use evaluation scoped to check whether the addition is actually being used the way the committee approved it for. Non-drug clinical products (devices, supplies) typically route through a separate body rather than the P&T committee — see Value Analysis Committee: How Hospital Approval Works for how that adjacent process works and where the two committees’ scopes divide.
Conflict-of-interest policy
This is the section a charter most often under-specifies, and it is the one the guide’s angle centers on. ASHP’s position is direct: voting members “should be required to provide COI statements to avoid actual or perceived interference with evidence-based decisions.” Institutions differ on the consequence — some exclude a conflicted member from voting entirely on the affected item, others allow the member to participate in discussion but not cast a vote — and a charter needs to state which model it uses rather than leaving the resolution to the meeting chair in the moment. ASHP also extends the disclosure obligation past the committee itself: “practitioners requesting additions or changes to the formulary should also be required to disclose financial relationships” relevant to the request, since the requesting prescriber is as capable of an undisclosed conflict as a voting member.
A complete COI section in a charter should specify, at minimum:
- What must be disclosed (industry payments, consulting/speaker relationships, equity, research funding) and how recently (most institutions use a 12-month look-back).
- When disclosure happens — annually at minimum, plus item-specific disclosure before any vote where a member’s relationship touches the product under review.
- The consequence: recusal from voting, recusal from discussion entirely, or documented participation with the conflict noted in the minutes.
- The same disclosure requirement applied to any non-member prescriber bringing a formulary request to the committee.
Standing agenda and the documentation trail
A well-specified charter produces a predictable, auditable agenda rather than an ad hoc one. Recurring items typically include: formulary additions, deletions, and scheduled therapeutic-class reviews; medication-use-evaluation reports and the corrective actions they generated; adverse-drug-event and medication-error trends surfaced through the hospital’s reporting system; drug shortages and any therapeutic-interchange decisions made to manage them; and COI disclosures logged for the period. Each of these connects to work the committee’s own criteria and voting rules are supposed to govern — a formulary addition without a documented literature review, or a shortage-driven interchange decided without a recorded vote, is the kind of gap a charter with clear criteria and voting rules is built to prevent.
On what a surveyor specifically checks for at the standard/element-of-performance level: Joint Commission’s Medication Management chapter language could not be independently verified against the primary manual for this page (jointcommission.org is not reachable to automated retrieval), so no specific standard or EP number is asserted here. What is verifiable is the underlying federal requirement the charter has to satisfy — the medical staff’s 482.25(b)(9) obligation to establish a formulary system, and the 482.25(b)(6) requirement that medication errors and adverse reactions reach the QAPI program. A charter that keeps a clean voting record, documented criteria per decision, and logged COI disclosures is producing the evidence trail that both a CMS surveyor and an accreditor’s medication-management review are actually looking for, independent of the exact citation.
Related CASRAI coverage
For the process a P&T committee itself commissions when it needs data on how a medication is actually being used, see Medication Use Evaluation (MUE): Criteria, Sampling, the Data Form, and the P&T Report. For adverse-drug-event trends that typically feed the committee’s standing agenda, see Adverse Drug Event Surveillance: Trigger Tools and Pharmacy-Based Screening. For the parallel governance body that reviews non-drug clinical products, see Value Analysis Committee: How Hospital Approval Works. For the broader patient-safety and infection-prevention cluster this page belongs to, see the Patient Safety pillar.
Frequently asked questions
What is a Pharmacy and Therapeutics committee charter?
It is the medical-staff governance document that specifies how a hospital’s P&T committee operates: who serves and who votes, quorum and voting procedure, the criteria applied to formulary decisions, and the conflict-of-interest policy governing members and requesting prescribers. It operationalizes the federal requirement (42 CFR 482.25(b)(9)) that the medical staff establish a formulary system.
Who has to be on a hospital P&T committee?
ASHP’s guideline describes voting membership as drawn from facility medical staff, other prescribers, pharmacists, nurses, and administrators, with additional non-voting participation from roles like quality-improvement, medication safety, informatics, and patient/family engagement. It does not set a fixed number of seats — the charter should name which specific roles vote.
Does the charter need to specify a quorum?
Yes. ASHP identifies quorum definition, vote-delegation rules, and voting method (including whether roll-call votes are used) as required administrative components of the committee’s structure, though it leaves the specific numbers to the institution.
How should a P&T committee charter handle conflicts of interest?
Voting members should be required to disclose COIs, with the charter stating the consequence (recusal from the vote, or from discussion entirely). The same disclosure requirement should extend to any non-member prescriber requesting a formulary addition or change.
Is a P&T committee the same as a Value Analysis Committee?
No. A P&T committee governs drug formulary decisions; a Value Analysis Committee (VAC) typically reviews non-drug clinical products such as devices and supplies. Charters for the two committees should state clearly which requests route to which body, since some products (drug-device combinations, for example) can sit at the boundary.
